

**Registered Office:**

Plot No. PF21 & PF-22/A, Charal Industrial Estate,  
Sanand GIDC-II, Sanand,  
Ahmedabad- 382110, Gujarat.

**CIN.: L24230GJ2015PLC085451**

**Date:** February 11, 2026

To,  
**The Manager-Listing**  
**National Stock Exchange of India Limited**  
Exchange Plaza, Bandra Kurla Complex,  
Mumbai – 400051

**Respected Sir/Ma'am,**

**Sub: Update under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015-Receipt of Purchase Order.**

***Ref: Sotac Pharmaceuticals Limited (SYMBOL/ISIN: SOTAC/INE002D01012)***

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that our Company has received a **Purchase Order** from **Cadila Pharmaceuticals Limited** dated February 10, 2026, via mail on February 11, 2026 amounting to **Rs. 1,38,65,271/-** i.e. (Rupees One Crore Thirty-Eight Lakh Sixty-Five Thousand Two Hundred Seventy-One Only) exclusive of GST for supply of various finished pharmaceutical formulations (Tablets, capsules, lotions, gels, and sprays).

This order provides the Company with an opportunity to demonstrate its manufacturing capabilities and to further strengthen its relationship with the customer, contributing positively to its business prospects.

***Further Details with respect to said order as required under regulation 30 of listing regulations read with SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, is enclosed as Annexure A.***

You are requested to kindly note the same.

Thanking you.

Yours faithfully,  
**For, Sotac Pharmaceuticals Limited**

**Sharadkumar Dashrathbhai Patel**  
**Chairman and Managing Director**  
**DIN: 07252252**

**Place:** Ahmedabad

**Encl:** A/a-

**Registered Office:**

Plot No. PF21 & PF-22/A, Charal Industrial Estate,  
Sanand GIDC-II, Sanand,  
Ahmedabad- 382110, Gujarat.

**CIN.: L24230GJ2015PLC085451****Annexure A**

**Details with respect to said order as required under regulation 30 of listing regulations read with SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, are attached herewith:**

| Sr. No. | Particulars                                                                                                                                                                   | Details                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1.      | Name of the entity awarding the order(s)/contract(s);                                                                                                                         | Cadila Pharmaceuticals Limited                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| 2.      | Whether order(s) / contract(s) have been awarded by domestic/ <del>international entity</del> ;                                                                               | Domestic                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 3.      | Nature of Contract, significant terms and conditions of order awarded, broad commercial consideration or size of the order;                                                   | <p>The Company has received a purchase order from Cadila Pharmaceuticals Limited for supply of various finished pharmaceutical formulations (Tablets, capsules, lotions, gels, and sprays)</p> <p>The total order value is <b>Rs. 1,38,65,271/-</b> i.e. (Rupees One Crore Thirty-Eight Lakh Sixty-Five Thousand Two Hundred Seventy-One Only) exclusive of GST.</p> <p><b>Significant Terms:</b><br/><b>Payment Terms:</b> 30 Days (credit)<br/><b>Terms of Dispatch:</b> Ex-work</p> |
| 4.      | Time period by which the order(s)/contract(s) is to be executed;                                                                                                              | <b><u>Delivery Schedule:</u></b><br>Staggered supplies between January 20, 2026 to March 31, 2026.                                                                                                                                                                                                                                                                                                                                                                                     |
| 5.      | Whether the promoter/ promoter group / group companies have any interest in the entity that awarded the order(s)/contract(s)? If yes, nature of interest and details thereof; | No                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 6.      | Whether the order(s)/contract(s) would fall within related party transactions? If yes, whether the same is done at "arm's length".                                            | No                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

**For, Sotac Pharmaceuticals Limited**

**Sharadkumar Dashrathbhai Patel**  
**Chairman and Managing Director**  
**DIN: 07252252**

**Place: Ahmedabad**